IL13 and COVID-19: The potential pathway through which dupilumab helps patients recover from COVID-19 might be that dupilumab restricts the duplication of SARS-CoV-2 and alleviates the abnormal immune responses in AD patients, possibly by blocking the augmented reaction caused by IL-4 and IL-13.